European Crude Heparin Market to Reach €1332.4 Million by 2030 at 5.1% CAGR

In 2023, the European market size of Crude Heparin was estimated to be worth €940.6 million and is forecast to reach approximately €1332.4 million by 2030 with a CAGR of 5.1% during the forecast period 2024-2030.

According to QY Research, Bioiberica S.A.U., a key player in the European crude heparin market, has made notable progress through a strategic partnership with the Vall Companys agri-food group. In May 2023, the two organizations launched Biovall Heparin Science, a joint venture focused on the sustainable production of crude heparin from porcine intestinal mucosa. This €25 million investment highlights Spain’s strong position in the global heparin supply chain, contributing approximately 20% of worldwide production. The project also reinforces Bioiberica’s commitment to circular economy practices and is expected to generate 20 specialized jobs in the sector.

Sanofi, another major company in the European crude heparin industry, has advanced its global health outreach through its not-for-profit Impact brand portfolio. As reported by QY Research, in October 2023 Sanofi delivered its first batch of medicines from this portfolio to Djibouti, including Enoxaparin Sodium Impact—an anticoagulant used in the treatment of venous thromboembolism such as deep vein thrombosis. This initiative is part of Sanofi’s broader mission to enhance equitable access to essential medicines in underserved regions, with a goal to reach 2 million people affected by noncommunicable diseases by 2030.

European Crude Heparin Top 20 Players Ranking and Market Share (Ranking is based on the revenue of 2024, continually updated)

Bioiberica S.A.U. (Spain)
Sanofi (France)
Rovi Pharma Industrial Services S.A. (Spain)
Pfizer Inc. (United States)
Techdow Pharma (China)
Aspen Pharmacare (South Africa)
Laboratorios Farmacéuticos Rovi S.A. (Spain)
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
Opocrin S.p.A. (Italy)
Fresenius Kabi (Germany)
Hikma Pharmaceuticals (United Kingdom)
Viatris/Mylan (United States)
Mitim Srl (Italy)
Syntex S.A. (Argentina)
Yantai Dongcheng Pharmaceutical Group (China)
Sichuan Deebio Pharmaceutical Co., Ltd. (China)
Rotexmedica GmbH (Germany)
Sandoz (Switzerland)
Italfarmaco S.p.A. (Italy)
BBCA Pharmaceuticals (China)

Crude Heparin, European Market Size, Split by Region


Crude Heparin, European Market Size, Split by Product Segment


Crude Heparin, European Market Size, Split by Application Segment

Based on or includes research from QYResearch: Global and European Crude Heparin Market Report 2025-2031

 

 

Related Market Reports From QY Research

 

QY Research Releases Comprehensive Market Reports on the Crude Heparin Market, as shown in the links below. These reports provide an in-depth analysis of the current market landscape, key trends, and future growth opportunities. If you need customized reports for specific European countries or regions, please feel free to contact us.

 

Global Crude Heparin Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

https://www.qyresearch.com/reports/4688760/crude-heparin

Global Crude Heparin Market Research Report 2025

https://www.qyresearch.com/reports/3440962/crude-heparin

Crude Heparin- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

https://www.qyresearch.com/reports/3438593/crude-heparin

 

 

Contact Information

QY Research Switzerland

Chemin des Mines 2, 1202 Geneva, GE

+41765899438

John Yaoen Wang

john@qyresearch.com

https://www.qyresearch.com/